Literature DB >> 8664771

Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry.

K Bloor1, A Maynard, N Freemantle.   

Abstract

This is the third of three papers that review international policies to control spending on drugs and to improve the efficiency of drug use. This paper reviews policies regulating the supply of drugs, particularly licensing and reimbursement controls, price and profit regulation. Price and profit controls contain few incentives for improving cost effective use of drugs, and focus on cost containment and profitability of domestic industry. Carefully monitored economic evaluation could lead to improvements in efficiency and benefits to patients and the health care system.

Entities:  

Mesh:

Year:  1996        PMID: 8664771      PMCID: PMC2351415          DOI: 10.1136/bmj.313.7048.33

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  11 in total

1.  A comparative analysis of the pharmaceutical market in four European countries.

Authors:  L Garattini; F Salvioni; D Scopelliti; S Garattini
Journal:  Pharmacoeconomics       Date:  1994-11       Impact factor: 4.981

2.  Regulations controlling costs of drugs: a perspective from the US.

Authors:  J S Lyons; D B Larson
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

3.  Economic impact of cost-containment strategies in third party programmes in the US (part I).

Authors:  C E Reeder; E W Lingle; R M Schulz; R P Mauch; B S Nightengale; C A Pedersen; M L Watrous; S E Zetzl
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

4.  New developments in pricing and drug reimbursement in France.

Authors:  A Pelc; J P Castan
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

5.  Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement.

Authors:  H Rigter
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

6.  Promoting cost effective prescribing.

Authors:  N Freemantle; D Henry; A Maynard; G Torrance
Journal:  BMJ       Date:  1995-04-15

7.  The German health care system at the crossroads.

Authors:  J M vd Schulenburg
Journal:  Health Econ       Date:  1994 Sep-Oct       Impact factor: 3.046

8.  The pharmaceutical industry and health reform: lessons from Europe.

Authors:  J Hutton; M Borowitz; I Oleksy; B R Luce
Journal:  Health Aff (Millwood)       Date:  1994       Impact factor: 6.301

9.  Pricing and reimbursement of pharmaceuticals in Sweden.

Authors:  B Jönsson
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

10.  International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.

Authors:  D J Gross; J Ratner; J Perez; S L Glavin
Journal:  Health Care Financ Rev       Date:  1994
View more
  14 in total

1.  Mega-mergers in the pharmaceutical industry. In whose interests?

Authors:  A L Po
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

Review 2.  Drug rationing in the UK National Health Service. Current status and future prospects.

Authors:  T Walley; A Haycox; S Barton
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

Review 3.  Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.

Authors:  Lisa L Ioannides-Demos; Joseph E Ibrahim; John J McNeil
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  US pharmaceutical innovation in an international context.

Authors:  Salomeh Keyhani; Steven Wang; Paul Hebert; Daniel Carpenter; Gerard Anderson
Journal:  Am J Public Health       Date:  2010-04-19       Impact factor: 9.308

Review 5.  Pharmacy utilization and the Medicare Modernization Act.

Authors:  Vittorio Maio; Laura Pizzi; Adam R Roumm; Janice Clarke; Neil I Goldfarb; David B Nash; David Chess
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

Review 6.  Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist.

Authors:  E Moen; E L Toverud; J Grund; S Brinchmann
Journal:  Pharm World Sci       Date:  1998-06

Review 7.  Successes, challenges and developments in Australian rheumatology.

Authors:  Eric F Morand; Michelle T Leech
Journal:  Nat Rev Rheumatol       Date:  2015-03-10       Impact factor: 20.543

Review 8.  Customising an international disease management model to the needs of individual countries. Application to upper gastrointestinal disease.

Authors:  A Haycox; D Dubois; M Butterworth
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 9.  Strategies to improve the cost effectiveness of general practitioner prescribing. An international perspective.

Authors:  H McGavock
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

10.  Drug reimbursement: indicators of inappropriate resource allocation.

Authors:  Bernard Bégaud; Ulf Bergman; Hans-Georg Eichler; Hubert G M Leufkens; Peter J Meier
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.